ADAR1 Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

ADAR1 Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$201K	Hold	10,000	–	–	0.01%	260
2025 Q4	$162K	Hold	10,000	–	–	0.01%	233
2025 Q3	$122K	Hold	10,000	–	–	0.01%	199
2025 Q2	$113K	Sell	10,000 -25,743	-72%	-$315K	0.02%	171
2025 Q1	$412K	Sell	35,743 -100	-0.3%	-$1.02K	0.08%	117
2024 Q4	$304K	Buy	35,843 +21,700	+153%	+$225K	0.06%	136
2024 Q3	$164K	Buy	14,143 +2,123	+18%	+$26.7K	0.03%	171
2024 Q2	$142K	Buy	12,020 +2,020	+20%	+$23.6K	0.03%	156
2024 Q1	$119K	Buy	+10,000	New	+$133K	0.03%	141

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ADAR1 Capital Management's KALV Position: Q1 2026 in Review

ADAR1 Capital Management held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 10,000 shares worth $201K. The position accounts for 0.01% of the portfolio, ranked #260.

ADAR1 Capital Management first reported a position in KALV in Q1 2024 and has held it in 9 quarters since. The position peaked at $412K in Q1 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

ADAR1 Capital Management held 10,000 shares of KalVista Pharmaceuticals worth $201K as of Q1 2026.
ADAR1 Capital Management left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
KalVista Pharmaceuticals made up 0.01% of ADAR1 Capital Management's portfolio in Q1 2026, its #260 holding.
ADAR1 Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
ADAR1 Capital Management's KalVista Pharmaceuticals position peaked at $412K in Q1 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.